^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)

    i
    Other names: PPM1G, Protein Phosphatase, Mg2+/Mn2+ Dependent 1G, PP2CG, Protein Phosphatase Magnesium-Dependent 1 Gamma, Protein Phosphatase 1G, Protein Phosphatase 1C, PP2C-Gamma, PP2Cgamma, Protein Phosphatase 1G (Formerly 2C), Magnesium-Dependent, Gamma Isoform, Protein Phosphatase, Mg2+/Mn2+ Dependent, 1G, Protein Phosphatase 2C, Gamma Isoform, Protein Phosphatase 2C Isoform Gamma, PP2C, Gamma, PP2CGAMMA, PPP2CG, PPM1C
    Associations

    News

    Trials
    3ms
    A Macrophage-Derived 7-Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma. (PubMed, IUBMB Life)
    Conversely, the high-risk group exhibited distinct genomic features and was predicted to be more sensitive to specific targeted agents, including Navitoclax and Sorafenib. We identified and validated a novel 7-gene prognostic signature derived from a subpopulation of EGFR-TKI-resistant macrophages. This signature accurately predicts patient survival, offers insights into the molecular mechanisms of therapy resistance in HCC, and provides a promising tool for improved patient stratification and the development of personalized treatment strategies.
    Journal • Gene Signature • IO biomarker
    |
    FAM83D (Family With Sequence Similarity 83 Member D) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • SLC41A3 (Solute Carrier Family 41 Member 3)
    |
    sorafenib • navitoclax (ABT 263)
    3ms
    Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med)
    Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POLD1 (DNA Polymerase Delta 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • ENO1 (Enolase 1) • YBX1 (Y-Box Binding Protein 1) • CTNND1 (Catenin Delta 1) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • ITGB1 (Integrin Subunit Beta 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    Vectibix (panitumumab)
    5ms
    PPM1G promotes chemoresistance in triple negative breast cancer by enhancing YAP signaling. (PubMed, Pharmacol Res)
    Moreover, treatment with a YAP inhibitor Verteporfin significantly attenuated the PPM1G-induced chemoresistance both in vitro and in vivo. Overall, our study elucidated a role of the PPM1G/NDR1/YAP axis in TNBC chemoresistance. We proposed that PPM1G may serve as a predictive biomarker for the treatment response of TNBC to YAP inhibitor.
    Journal
    |
    NDRG1 (N-Myc Downstream Regulated 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    |
    Visudyne (verteporfin)
    6ms
    Overexpression of PPM1G promotes cell metabolism and activates the NOTCH signaling pathway in lung adenocarcinoma. (PubMed, Transl Lung Cancer Res)
    Our results revealed that high PPM1G expression acted as a prognostic factor in LUAD and promoted LUAD cell growth, metastasis, and glycolysis. Mechanistically, PPM1G activated the NOTCH pathway to promote these effects, indicating its potential as a novel therapeutic target for treating LUAD.
    Journal
    |
    PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    over1year
    PPM1G Inhibits Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter. (PubMed, Adv Sci (Weinh))
    Two phosphatase inhibitors, staurosporine and AZD0156, inhibit epithelial-to-mesenchymal transition (EMT) in cholangiocarcinoma cells by suppressing TET1 expression. In conclusion, it is also demonstrated that PPM1G can be employed as a therapeutic target to impede the progression of CCA by catalyzing the dephosphorylation of TET1, which diminishes the capacity of TET1 to target the CLDN3 promoter to activate transcription and inhibit EMT in CCA.
    Journal
    |
    TET1 (Tet Methylcytosine Dioxygenase 1) • CLDN3 (Claudin 3) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    |
    AZD0156
    over1year
    PPM1G-mediated TBL1X mRNA splicing promotes cell migration in hepatocellular carcinoma. (PubMed, Cancer Sci)
    In conclusion, our study highlights the biological role of PPM1G and TBL1X-S in tumor metastasis. The PPM1G/TBL1X-S signaling axis presents a new view for investigating liver cancer metastasis mechanisms.
    Journal
    |
    CDH1 (Cadherin 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    over1year
    Ubiquitin-related gene markers predict immunotherapy response and prognosis in patients with epithelial ovarian carcinoma. (PubMed, Sci Rep)
    It also exhibited lower tumor mutation burden, mRNAsi, and EREG-mRNAsi and reduced sensitivity to other chemotherapy drugs, except dasatinib. These findings serve as a valuable indicator for personalized treatment strategies and clinical stratification in managing patients with EOC. Additionally, our study will serve as a foundation for future mechanistic research to explore the association between the ubiquitin-proteasome pathway and EOC.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule) • EREG (Epiregulin) • STAT1 (Signal Transducer And Activator Of Transcription 1) • VPS18 (VPS18 Core Subunit Of CORVET And HOPS Complexes) • AKAP12 (A-Kinase Anchoring Protein 12) • FBXO9 (F-Box Protein 9) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    |
    TMB-L
    |
    dasatinib
    over1year
    PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review). (PubMed, Int J Oncol)
    In the present review, the regulatory role of PPM1G in diverse biological processes and signaling pathway activation in eukaryotes is evaluated. Furthermore, its potential application as a biomarker in the diagnosis and prognosis evaluation of HCC is assessed, and future prospects for HCC treatment strategies centered on PPM1G are discussed.
    Review • Journal
    |
    PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    over1year
    PPM1G promotes autophagy and progression of pancreatic cancer via upregulating HMGB1. (PubMed, Cell Signal)
    Additionally, patients with both high PPM1G and high HMGB1 exhibited poorer prognosis in our cohort. This study preliminarily investigated the possibility of PPM1G as a potential therapeutic target and prognostic biomarker in pancreatic cancer patients.
    Journal
    |
    SQSTM1 (Sequestosome 1) • HMGB1 (High Mobility Group Box 1) • BECN1 (Beclin 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    over1year
    PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation. (PubMed, Life Sci Alliance)
    We describe the eIF4E-binding motif in PPM1G that is similar to 4E-binding proteins (4E-BPs). We demonstrate that PPM1G inhibits cell proliferation by targeting phospho-eIF4E-dependent mRNA translation.
    Journal
    |
    PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    2years
    PPM1G promotes cell proliferation via modulating mutant GOF p53 protein expression in hepatocellular carcinoma. (PubMed, iScience)
    Besides, the immunoprecipitation analysis revealed a direct interaction between PPM1G and GOF mutant p53. Collectively, PPM1G can be a powerful prognostic predictor and potential drug-target molecule.
    Journal
    |
    TP53 (Tumor protein P53) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)
    |
    TP53 mutation • TP53 expression
    2years
    PPM1G regulates hepatic ischemia/reperfusion injury through STING-mediated inflammatory pathways in macrophages. (PubMed, Immun Inflamm Dis)
    PPM1G suppresses hepatic IRI and macrophage M1 phenotype by repressing STING-mediated inflammatory pathways.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • STING (stimulator of interferon response cGAMP interactor 1) • IL10 (Interleukin 10) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)